1. Hyaluronidase from ATCC 31394, comprising the N-terminal amino acid sequence shown in SEQ ID No 1.2. The hyaluronidase according to claim 1, having a molecular weight of 21.6 kDa, an isoelectric point (pI) in the range of 4.4 to 4.8, and an enzymatic activity equal to or greater than 40,000 IU / mg. The method for producing hyaluronidase according to claim 1 or 2, comprising the following steps: a) chromatography on a weak cation exchanger of the supernatant obtained after fermentation of ATCC 31394 and isolating a protein fraction exhibiting hyaluronidase activity; b) diafiltration and chromatography on a strong anion exchanger of a protein fraction exhibiting hyaluron activity from step a) and isolating the protein fraction exhibiting hyaluronidase activity; c) chromatography on a strong cation exchanger of the protein fraction exhibiting hyaluronidase activity of step b), and isolating the protein fraction exhibiting hyaluronidase activity; d) chromatography on a strong anion exchanger protein fraction exhibiting hyaluronidase activity from step c), and isolating the protein fraction exhibiting hyaluronidase aktivnost.4. The hyaluronidase according to claim 1 or 2 for use as a medicine. The hyaluronidase according to claim 4 for use in the treatment of diseases for which decomposition of hyaluronic acid in damaged tissues or organs is required or useful. Hyaluronidase for use according to claim 5, wherein the disease is selected from edema, inflammation, chills, solid tumors, IgE-mediated allergies, oral diseases and spontaneous bleeding of the vitreous. Hyaluronidase for use according to claim 5, wherein the disease is bovine mastitis. Pharmaceutical
展开▼
